Orasure Technologies Inc. (OSUR)
Summary
OSUR Chart
OraSure Technologies, Inc. (OSUR) Q1 2026 Earnings Call Transcript
OraSure Technologies, Inc. (OSUR) Q1 2026 Earnings Call Transcript
OraSure Files for FDA Review of Molecular Self-Test & Colli-Pee Device
OSUR files FDA applications seeking approval for two at-home STI tests, advancing decentralized diagnostics; shares gain 3.8% as it targets long-term growth.
OraSure Technologies, Inc. (OSUR) Q3 2025 Earnings Call Transcript
OraSure Technologies, Inc. ( OSUR ) Q3 2025 Earnings Call November 5, 2025 5:00 PM EST Company Participants Jason Plagman - Vice President of Investor Relations Carrie Eglinton Manner - President, CEO & Director Kenneth McGrath - Chief Financial Officer Conference Call Participants Steven Etoch - Stephens Inc., Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the OraSure Technologies, Inc. 2025 Third Quarter Earnings Conference Call.
Orasure Technologies Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TMB Timothy M. Bidwell Hazlett, BURT & WATSON Inc. | 1,500 | $10,170 | $6,397.5 | -$3,772.5 | -37.09% |
| CE Curtis Ellergodt Rothschild Investment LLC | 35 | $105 | $149.27 | $44.27 | 42.16% |
| BG Bart Gancher Intech Investment Management LLC | 18,853 | $57,427.39 | $79,465.39 | $22,038 | 38.38% |
| YA Yinka Akinsola Blue Trust Inc. | 253 | $685.63 | $1,067.66 | $382.03 | 55.72% |
 Joseph Castro Nuveen LLC | 159,359 | $478,077 | $670,901.39 | $192,824.39 | 40.33% |
Orasure Technologies Inc. (OSUR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Orasure Technologies Inc. ever had a stock split?
Orasure Technologies Inc. Profile
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Carrie Eglinton Manner CEO | NASDAQ (NGS) Exchange | 68554V108 CUSIP |
| US Country | 501 Employees | 8 Jan 1998 Last Dividend | 8 Apr 1987 Last Split | 12 Nov 1986 IPO Date |
Overview
OraSure Technologies, Inc., founded in 2000 and headquartered in Bethlehem, Pennsylvania, operates globally offering a wide range of diagnostic solutions, specimen collection devices, and microbiome laboratory services. The company plays a pivotal role in public health by providing innovative products for the diagnosis of critical conditions such as HIV, hepatitis C (HCV), Ebola, and COVID-19 along with substance abuse testing. OraSure’s commitment to improving healthcare accessibility is evident in its development of both point-of-care and home diagnostic tests, catering to a diverse clientele including clinical laboratories, hospitals, public health organizations, and more. Their offerings have found international application in various sectors including healthcare, government, and environmental markets, making it a significant player in the diagnostics field.
Products and Services
The comprehensive range of products and services from OraSure Technologies, Inc. underscores its mission to deliver reliable and convenient diagnostic solutions:
- COVID-19 Rapid Tests: The InteliSwab COVID-19 rapid tests including versions for professional and Rx use, offer quick and easy solutions for detecting the COVID-19 virus, simplifying testing across settings.
- HIV Testing Solutions: Products such as OraQuick Rapid HIV test, the In-Home HIV test, and the HIV self-test facilitate prompt, private, and accurate HIV testing.
- HCV Rapid Antibody Test: The OraQuick HCV test provides rapid detection of hepatitis C antibodies, making HCV screening more accessible.
- Ebola Rapid Antigen Test: This test offers critical rapid diagnostic capabilities for Ebola virus detection, particularly significant in epidemic responses.
- Oral Fluid Collection Device: Used for screening and confirmatory tests for HIV-1 antibodies, enhancing the ease and safety of sample collection.
- Intercept Drug Testing Systems: These systems cater to the need for reliable drug abuse testing in various settings.
- Q.E.D. Saliva Alcohol Test: Offers a simple and effective means for detecting alcohol levels, ensuring workplace and road safety.
- Genomic Products: Including Oragene and ORAcollect brands, these products streamline the collection of genetic material from saliva for diverse genetic analyses.
- Urine Sample Collection: The Colli-Pee devices facilitate the volumetric collection of urine samples, optimizing specimen collection for diagnostics.
- Microbiome Laboratory Testing and Services: Through platforms like OMNIgene GUT, the company offers comprehensive solutions for gut microbiome profiling, supporting a burgeoning field in human health research.
- Immunoassay Tests and Reagents: A variety of diagnostic products fall under this category, providing essential tools for the detection of various pathogens and conditions.
These offerings underline OraSure Technologies, Inc.'s commitment to advancing health diagnostics, ensuring that critical health information is accessible, reliable, and timely.
